(Saunders & Yudin, 2022)

(L'Exact et al., 2023)

(Lampa et al., 2014)

(Yamaguchi-Sasaki et al., 2020)

(Lindsley et al., 2007)

(Moore et al., 2007)

(Raboisson, de Kock, et al., 2008)

(Raboisson, Lin, et al., 2008)

(Vendeville et al., 2008)

(Machauer et al., 2009)

(Lerchner et al., 2010)

(Nilsson et al., 2010)

(Sund et al., 2011)

(Duan et al., 2012)

(McGowan et al., 2012)

(Maccari et al., 2014)

(Parsy et al., 2015)

(Boy et al., 2015)

(Ladziata et al., 2016)

(Granger & Brown, 2016)

(Farand et al., 2016)

(Wurtz et al., 2017)

(Corte, Yang, et al., 2017)

(Clark et al., 2019)

(Fang et al., 2020)

(Miyachi et al., 2021)

(Xiao et al., 2021)

(Basit et al., 2017)

(Wang et al., 2016)

(Le Roux et al., 2020)

(Yang et al., 2020)

(Randolph et al., 2020)

(Tess et al., 2020)

(Zhang et al., 2021)

(Kostrun et al., 2021)

(Zheng et al., 2021)

(Dilger et al., 2021)

(Liu et al., 2021)

(Wuelfing et al., 2022)

(Begnini et al., 2022)

(Rzepiela et al., 2022)

(Zhang et al., 2022)

(Wang et al., 2022)

(Kettle et al., 2016)

(Andersson et al., 2016)

(Zhang et al., 2016)

(Corte, Fang, et al., 2017)

(Wang et al., 2017)

(McCoull et al., 2017)

(DeGoey et al., 2017)

(Giroud, Dietzel, et al., 2018)

(Rossi Sebastiano et al., 2018)

(Mackman et al., 2018)

(Li et al., 2018)

(Naylor et al., 2018)

(Engelhardt et al., 2019)

(Himmelbauer et al., 2019)’

(Rescourio et al., 2019)

(Houštecká et al., 2020)

(Corte et al., 2019)

(Stefanucci et al., 2019)

(Hostalkova et al., 2019)

(Tyagi et al., 2018)

(Spencer et al., 2020)

(Begnini et al., 2021)

(Cee et al., 2016)

(Richter et al., 2017)

(Li et al., 2017)

(Kaneda et al., 2018)

(Hopkins et al., 2019)

(Xin et al., 2020)

(Liederer et al., 2006)

(Stachel et al., 2006)

(Hess et al., 2007)

(William et al., 2011)

(Hoveyda et al., 2011)

(William, Lee, Goh, et al., 2012)

(William, Lee, Poulsen, et al., 2012)

(Moreau et al., 2014)

(Jiang et al., 2014)

(Joshi et al., 2013)

(Rosenquist et al., 2014)

(Johnson et al., 2014)

(Peng et al., 2010)

(Halland et al., 2014)

(Over et al., 2016)

(Xu et al., 2017)

(Lin et al., 2011)

(Ahlbach et al., 2015)

(MARSAULT et al., 2008)

(Yang et al., 2023)

(Nožinić et al., 2010)

(Wieske et al., 2023)

(Giordanetto & Kihlberg, 2014)

(Du-Cuny et al., 2009)

(Gozalbes et al., 2011)

(Jing et al., 2014)

(Xue et al., 2020)

(Begnini et al., 2020)

(Giroud, Kuhn, et al., 2018)

(Pasero et al., 2018)

(Do et al., 2019)

(Adebesin et al., 2019)

(Giordanetto & Kihlberg, 2014)

Adebesin, A. M., Wesser, T., Vijaykumar, J., Konkel, A., Paudyal, M. P., Lossie, J., Zhu, C., Westphal, C., Puli, N., & Fischer, R. (2019). Development of robust 17 (R), 18 (S)-epoxyeicosatetraenoic acid (17, 18-EEQ) analogues as potential clinical antiarrhythmic agents. *Journal of medicinal chemistry*, *62*(22), 10124-10143.

Ahlbach, C. L., Lexa, K. W., Bockus, A. T., Chen, V., Crews, P., Jacobson, M. P., & Lokey, R. S. (2015). Beyond cyclosporine A: conformation-dependent passive membrane permeabilities of cyclic peptide natural products. *Future medicinal chemistry*, *7*(16), 2121-2130.

Andersson, V., Bergstrom, F., Branalt, J., Gronberg, G., Gustafsson, D., Karlsson, S., Polla, M., Bergman, J., & Kihlberg, J. (2016). Macrocyclic prodrugs of a selective nonpeptidic direct thrombin inhibitor display high permeability, efficient bioconversion but low bioavailability. *Journal of Medicinal Chemistry*, *59*(14), 6658-6670.

Basit, S., Ashraf, Z., Lee, K., & Latif, M. (2017). First macrocyclic 3rd-generation ALK inhibitor for treatment of ALK/ROS1 cancer: Clinical and designing strategy update of lorlatinib. *European Journal of Medicinal Chemistry*, *134*, 348-356.

Begnini, F., Geschwindner, S., Johansson, P., Wissler, L., Lewis, R. J., Danelius, E., Luttens, A., Matricon, P., Carlsson, J., & Lenders, S. (2022). Importance of binding site hydration and flexibility revealed when optimizing a macrocyclic inhibitor of the Keap1–Nrf2 protein–protein interaction. *Journal of Medicinal Chemistry*, *65*(4), 3473-3517.

Begnini, F., Poongavanam, V., Atilaw, Y., Erdelyi, M., Schiesser, S., & Kihlberg, J. (2021). Cell permeability of isomeric macrocycles: Predictions and NMR studies. *ACS Medicinal Chemistry Letters*, *12*(6), 983-990.

Begnini, F., Poongavanam, V., Over, B. r., Castaldo, M., Geschwindner, S., Johansson, P., Tyagi, M., Tyrchan, C., Wissler, L., & Sjö, P. (2020). Mining natural products for macrocycles to drug difficult targets. *Journal of medicinal chemistry*, *64*(2), 1054-1072.

Boy, K. M., Guernon, J. M., Wu, Y.-J., Zhang, Y., Shi, J., Zhai, W., Zhu, S., Gerritz, S. W., Toyn, J. H., & Meredith, J. E. (2015). Macrocyclic prolinyl acyl guanidines as inhibitors of β-secretase (BACE). *Bioorganic & Medicinal Chemistry Letters*, *25*(22), 5040-5047.

Cee, V. J., Chavez Jr, F., Herberich, B., Lanman, B. A., Pettus, L. H., Reed, A. B., Wu, B., Wurz, R. P., Andrews, K. L., & Chen, J. (2016). Discovery and optimization of macrocyclic quinoxaline-pyrrolo-dihydropiperidinones as potent pim-1/2 kinase inhibitors. *ACS Medicinal Chemistry Letters*, *7*(4), 408-412.

Clark, C. G., Rossi, K. A., Corte, J. R., Fang, T., Smallheer, J. M., De Lucca, I., Nirschl, D. S., Orwat, M. J., Pinto, D. J., & Hu, Z. (2019). Structure based design of macrocyclic factor XIa inhibitors: Discovery of cyclic P1 linker moieties with improved oral bioavailability. *Bioorganic & Medicinal Chemistry Letters*, *29*(19), 126604.

Corte, J. R., Fang, T., Osuna, H., Pinto, D. J., Rossi, K. A., Myers Jr, J. E., Sheriff, S., Lou, Z., Zheng, J. J., & Harper, T. W. (2017). Structure-based design of macrocyclic factor XIa inhibitors: Discovery of the macrocyclic amide linker. *Journal of Medicinal Chemistry*, *60*(3), 1060-1075.

Corte, J. R., Pinto, D. J., Fang, T., Osuna, H., Yang, W., Wang, Y., Lai, A., Clark, C. G., Sun, J.-H., & Rampulla, R. (2019). Potent, orally bioavailable, and efficacious macrocyclic inhibitors of factor XIa. Discovery of pyridine-based macrocycles possessing phenylazole carboxamide P1 groups. *Journal of Medicinal Chemistry*, *63*(2), 784-803.

Corte, J. R., Yang, W., Fang, T., Wang, Y., Osuna, H., Lai, A., Ewing, W. R., Rossi, K. A., Myers Jr, J. E., & Sheriff, S. (2017). Macrocyclic inhibitors of Factor XIa: Discovery of alkyl-substituted macrocyclic amide linkers with improved potency. *Bioorganic & Medicinal Chemistry Letters*, *27*(16), 3833-3839.

DeGoey, D. A., Chen, H.-J., Cox, P. B., & Wendt, M. D. (2017). Beyond the rule of 5: lessons learned from AbbVie’s drugs and compound collection: miniperspective. *Journal of Medicinal Chemistry*, *61*(7), 2636-2651.

Dilger, A. K., Pabbisetty, K. B., Corte, J. R., De Lucca, I., Fang, T., Yang, W., Pinto, D. J., Wang, Y., Zhu, Y., & Mathur, A. (2021). Discovery of milvexian, a high-affinity, orally bioavailable inhibitor of factor XIa in clinical studies for antithrombotic therapy. *Journal of Medicinal Chemistry*, *65*(3), 1770-1785.

Do, H. T., Li, H., Chreifi, G., Poulos, T. L., & Silverman, R. B. (2019). Optimization of Blood–Brain Barrier Permeability with Potent and Selective Human Neuronal Nitric Oxide Synthase Inhibitors Having a 2-Aminopyridine Scaffold. *Journal of medicinal chemistry*, *62*(5), 2690-2707. <https://doi.org/10.1021/acs.jmedchem.8b02032>

Du-Cuny, L., Song, Z., Moses, S., Powis, G., Mash, E. A., Meuillet, E. J., & Zhang, S. (2009). Computational modeling of novel inhibitors targeting the Akt pleckstrin homology domain. *Bioorganic & medicinal chemistry*, *17*(19), 6983-6992.

Duan, M., Kazmierski, W., Crosby, R., Gartland, M., Ji, J., Tallant, M., Wang, A., Hamatake, R., Wright, L., Wu, M., Zhang, Y. K., Ding, C. Z., Li, X., Liu, Y., Zhang, S., Zhou, Y., Plattner, J. J., & Baker, S. J. (2012). Discovery of novel P3-oxo inhibitor of hepatitis C virus NS3/4A serine protease. *Bioorg Med Chem Lett*, *22*(8), 2993-2996. <https://doi.org/10.1016/j.bmcl.2012.02.039>

Engelhardt, H., Böse, D., Petronczki, M., Scharn, D., Bader, G., Baum, A., Bergner, A., Chong, E., Döbel, S., & Egger, G. (2019). Start selective and rigidify: the discovery path toward a next generation of EGFR tyrosine kinase inhibitors. *Journal of Medicinal Chemistry*, *62*(22), 10272-10293.

Fang, T., Corte, J. R., Gilligan, P. J., Jeon, Y., Osuna, H., Rossi, K. A., Myers Jr, J. E., Sheriff, S., Lou, Z., & Zheng, J. J. (2020). Orally bioavailable amine-linked macrocyclic inhibitors of factor XIa. *Bioorganic & Medicinal Chemistry Letters*, *30*(4), 126949.

Farand, J., Mai, N., Chandrasekhar, J., Newby, Z. E., Van Veldhuizen, J., Loyer-Drew, J., Venkataramani, C., Guerrero, J., Kwok, A., & Li, N. (2016). Selectivity switch between FAK and Pyk2: Macrocyclization of FAK inhibitors improves Pyk2 potency. *Bioorganic & Medicinal Chemistry Letters*, *26*(24), 5926-5930.

Giordanetto, F., & Kihlberg, J. (2014). Macrocyclic drugs and clinical candidates: what can medicinal chemists learn from their properties? *Journal of medicinal chemistry*, *57*(2), 278-295.

Giroud, M., Dietzel, U., Anselm, L., Banner, D., Kuglstatter, A., Benz, J., Blanc, J.-B., Gaufreteau, D., Liu, H., & Lin, X. (2018). Repurposing a library of human cathepsin L ligands: identification of macrocyclic lactams as potent rhodesain and trypanosoma brucei inhibitors. *Journal of Medicinal Chemistry*, *61*(8), 3350-3369.

Giroud, M., Kuhn, B., Saint-Auret, S., Kuratli, C., Martin, R. E., Schuler, F., Diederich, F., Kaiser, M., Brun, R., & Schirmeister, T. (2018). 2 H-1, 2, 3-Triazole-based dipeptidyl nitriles: potent, selective, and trypanocidal rhodesain inhibitors by structure-based design. *Journal of medicinal chemistry*, *61*(8), 3370-3388.

Gozalbes, R., Jacewicz, M., Annand, R., Tsaioun, K., & Pineda-Lucena, A. (2011). QSAR-based permeability model for drug-like compounds. *Bioorganic & medicinal chemistry*, *19*(8), 2615-2624.

Granger, B. A., & Brown, D. G. (2016). Design and synthesis of peptide-based macrocyclic cyclophilin inhibitors. *Bioorganic & Medicinal Chemistry Letters*, *26*(21), 5304-5307.

Halland, N., Blum, H., Buning, C., Kohlmann, M., & Lindenschmidt, A. (2014). Small macrocycles as highly active integrin α2β1 antagonists. *ACS Medicinal Chemistry Letters*, *5*(2), 193-198.

Hess, S., Ovadia, O., Shalev, D. E., Senderovich, H., Qadri, B., Yehezkel, T., Salitra, Y., Sheynis, T., Jelinek, R., & Gilon, C. (2007). Effect of structural and conformation modifications, including backbone cyclization, of hydrophilic hexapeptides on their intestinal permeability and enzymatic stability. *Journal of Medicinal Chemistry*, *50*(24), 6201-6211.

Himmelbauer, M. K., Xin, Z., Jones, J. H., Enyedy, I., King, K., Marcotte, D. J., Murugan, P., Santoro, J. C., Hesson, T., & Spilker, K. (2019). Rational design and optimization of a novel class of macrocyclic apoptosis signal-regulating kinase 1 inhibitors. *Journal of Medicinal Chemistry*, *62*(23), 10740-10756.

Hopkins, B. A., Lee, H., Ha, S., Nogle, L., Sauvagnat, B., McMinn, S., Smith, G. F., & Sciammetta, N. (2019). Development of a platform to enable efficient permeability evaluation of novel organo-peptide macrocycles. *ACS Medicinal Chemistry Letters*, *10*(6), 874-879.

Hostalkova, A., Marikova, J., Opletal, L., Korabecny, J., Hulcova, D., Kunes, J., Novakova, L., Perez, D. I., Jun, D., & Kucera, T. (2019). Isoquinoline alkaloids from Berberis vulgaris as potential lead compounds for the treatment of Alzheimer’s disease. *Journal of natural products*, *82*(2), 239-248.

Houštecká, R., Hadzima, M., Fanfrlik, J., Brynda, J., Pallová, L., Hánová, I., Mertlíková-Kaiserová, H., Lepsik, M., Horn, M., & Smrčina, M. (2020). Biomimetic Macrocyclic Inhibitors of Human Cathepsin D: Structure–Activity Relationship and Binding Mode Analysis. *Journal of Medicinal Chemistry*, *63*(4), 1576-1596.

Hoveyda, H. R., Marsault, E., Gagnon, R., Mathieu, A. P., Vézina, M., Landry, A., Wang, Z., Benakli, K., Beaubien, S., & Saint-Louis, C. (2011). Optimization of the potency and pharmacokinetic properties of a macrocyclic ghrelin receptor agonist (Part I): development of ulimorelin (TZP-101) from hit to clinic. *Journal of Medicinal Chemistry*, *54*(24), 8305-8320.

Jiang, Y., Andrews, S. W., Condroski, K. R., Buckman, B., Serebryany, V., Wenglowsky, S., Kennedy, A. L., Madduru, M. R., Wang, B., & Lyon, M. (2014). Discovery of danoprevir (ITMN-191/R7227), a highly selective and potent inhibitor of hepatitis C virus (HCV) NS3/4A protease. *Journal of Medicinal Chemistry*, *57*(5), 1753-1769.

Jing, Y.-r., Zhou, W., Li, W.-l., Zhao, L.-x., & Wang, Y.-f. (2014). The synthesis of novel taxoids for oral administration. *Bioorganic & medicinal chemistry*, *22*(1), 194-203.

Johnson, T. W., Richardson, P. F., Bailey, S., Brooun, A., Burke, B. J., Collins, M. R., Cui, J. J., Deal, J. G., Deng, Y.-L., & Dinh, D. (2014). Discovery of (10 R)-7-Amino-12-fluoro-2, 10, 16-trimethyl-15-oxo-10, 15, 16, 17-tetrahydro-2H-8, 4-(metheno) pyrazolo [4, 3-h][2, 5, 11]-benzoxadiazacyclotetradecine-3-carbonitrile (PF-06463922), a macrocyclic inhibitor of anaplastic lymphoma kinase (ALK) and c-ros oncogene 1 (ROS1) with preclinical brain exposure and broad-spectrum potency against ALK-resistant mutations. *Journal of Medicinal Chemistry*, *57*(11), 4720-4744.

Joshi, A., Véron, J.-B., Unge, J., Rosenquist, Å., Wallberg, H., Samuelsson, B., Hallberg, A., & Larhed, M. (2013). Design and Synthesis of P1–P3 Macrocyclic Tertiary-Alcohol-Comprising HIV-1 Protease Inhibitors. *Journal of Medicinal Chemistry*, *56*(22), 8999-9007.

Kaneda, M., Kawaguchi, S., Fujii, N., Ohno, H., & Oishi, S. (2018). Structure–activity relationship study on odoamide: Insights into the bioactivities of Aurilide-family hybrid peptide–polyketides. *ACS Medicinal Chemistry Letters*, *9*(4), 365-369.

Kettle, J. G., Alwan, H., Bista, M., Breed, J., Davies, N. L., Eckersley, K., Fillery, S., Foote, K. M., Goodwin, L., & Jones, D. R. (2016). Potent and selective inhibitors of MTH1 probe its role in cancer cell survival. *Journal of Medicinal Chemistry*, *59*(6), 2346-2361.

Kostrun, S., Fajdetic, A., Pesic, D., Brajsa, K., Bencetić Mihaljević, V., Jelic, D., Petrinić Grba, A., Elenkov, I., Rupcic, R., & Kapic, S. (2021). Macrolide inspired macrocycles as modulators of the IL-17A/IL-17RA interaction. *Journal of Medicinal Chemistry*, *64*(12), 8354-8383.

L'Exact, M., Comeau, C., Bourhis, A., Boisvert, O., Fröhlich, U., Létourneau, D., Marsault, É., Lavigne, P., Grandbois, M., & Boudreault, P. L. (2023). Beyond Rule-of-five: Permeability Assessment of Semipeptidic Macrocycles. *Biochim Biophys Acta Biomembr*, *1865*(7), 184196. <https://doi.org/10.1016/j.bbamem.2023.184196>

Ladziata, V. U., Glunz, P. W., Zou, Y., Zhang, X., Jiang, W., Jacutin-Porte, S., Cheney, D. L., Wei, A., Luettgen, J. M., & Harper, T. M. (2016). Synthesis and P1′ SAR exploration of potent macrocyclic tissue factor-factor VIIa inhibitors. *Bioorganic & Medicinal Chemistry Letters*, *26*(20), 5051-5057.

Lampa, A., Alogheli, H., Ehrenberg, A. E., Åkerblom, E., Svensson, R., Artursson, P., Danielson, U. H., Karlén, A., & Sandström, A. (2014). Vinylated linear P2 pyrimidinyloxyphenylglycine based inhibitors of the HCV NS3/4A protease and corresponding macrocycles. *Bioorg Med Chem*, *22*(23), 6595-6615. <https://doi.org/10.1016/j.bmc.2014.10.010>

Le Roux, A., Blaise, E., Boudreault, P.-L., Comeau, C., Doucet, A., Giarrusso, M., Collin, M.-P., Neubauer, T., Kölling, F., & Göller, A. H. (2020). Structure–permeability relationship of semipeptidic macrocycles—understanding and optimizing passive permeability and efflux ratio. *Journal of Medicinal Chemistry*, *63*(13), 6774-6783.

Lerchner, A., Machauer, R., Betschart, C., Veenstra, S., Rueeger, H., McCarthy, C., Tintelnot-Blomley, M., Jaton, A. L., Rabe, S., Desrayaud, S., Enz, A., Staufenbiel, M., Paganetti, P., Rondeau, J. M., & Neumann, U. (2010). Macrocyclic BACE-1 inhibitors acutely reduce Abeta in brain after po application. *Bioorg Med Chem Lett*, *20*(2), 603-607. <https://doi.org/10.1016/j.bmcl.2009.11.092>

Li, D., Zhang, X., Ma, X., Xu, L., Yu, J., Gao, L., Hu, X., Zhang, J., Dong, X., & Li, J. (2018). Development of macrocyclic peptides containing epoxyketone with oral availability as proteasome inhibitors. *Journal of Medicinal Chemistry*, *61*(20), 9177-9204.

Li, Z., Partridge, J., Silva-Garcia, A., Rademacher, P., Betz, A., Xu, Q., Sham, H., Hu, Y., Shan, Y., & Liu, B. (2017). Structure-guided design of novel, potent, and selective macrocyclic plasma kallikrein inhibitors. *ACS Medicinal Chemistry Letters*, *8*(2), 185-190.

Liederer, B. M., Fuchs, T., Vander Velde, D., Siahaan, T. J., & Borchardt, R. T. (2006). Effects of amino acid chirality and the chemical linker on the cell permeation characteristics of cyclic prodrugs of opioid peptides. *Journal of Medicinal Chemistry*, *49*(4), 1261-1270.

Lin, X., Skolnik, S., Chen, X., & Wang, J. (2011). Attenuation of intestinal absorption by major efflux transporters: quantitative tools and strategies using a Caco-2 model. *Drug Metabolism and Disposition*, *39*(2), 265-274.

Lindsley, S. R., Moore, K. P., Rajapakse, H. A., Selnick, H. G., Young, M. B., Zhu, H., Munshi, S., Kuo, L., McGaughey, G. B., Colussi, D., Crouthamel, M. C., Lai, M. T., Pietrak, B., Price, E. A., Sankaranarayanan, S., Simon, A. J., Seabrook, G. R., Hazuda, D. J., Pudvah, N. T., Hochman, J. H., Graham, S. L., Vacca, J. P., & Nantermet, P. G. (2007). Design, synthesis, and SAR of macrocyclic tertiary carbinamine BACE-1 inhibitors. *Bioorg Med Chem Lett*, *17*(14), 4057-4061. <https://doi.org/10.1016/j.bmcl.2007.04.072>

Liu, Z., Yu, P., Dong, L., Wang, W., Duan, S., Wang, B., Gong, X., Ye, L., Wang, H., & Tian, J. (2021). Discovery of the next-generation pan-TRK kinase inhibitors for the treatment of cancer. *Journal of Medicinal Chemistry*, *64*(14), 10286-10296.

Maccari, G., Sanfilippo, S., De Luca, F., Deodato, D., Casian, A., Lang, M. C. D., Zamperini, C., Dreassi, E., Rossolini, G. M., & Docquier, J.-D. (2014). Synthesis of linear and cyclic guazatine derivatives endowed with antibacterial activity. *Bioorganic & Medicinal Chemistry Letters*, *24*(23), 5525-5529.

Machauer, R., Laumen, K., Veenstra, S., Rondeau, J. M., Tintelnot-Blomley, M., Betschart, C., Jaton, A. L., Desrayaud, S., Staufenbiel, M., Rabe, S., Paganetti, P., & Neumann, U. (2009). Macrocyclic peptidomimetic beta-secretase (BACE-1) inhibitors with activity in vivo. *Bioorg Med Chem Lett*, *19*(5), 1366-1370. <https://doi.org/10.1016/j.bmcl.2009.01.055>

Mackman, R. L., Steadman, V. A., Dean, D. K., Jansa, P., Poullennec, K. G., Appleby, T., Austin, C., Blakemore, C. A., Cai, R., & Cannizzaro, C. (2018). Discovery of a potent and orally bioavailable cyclophilin inhibitor derived from the sanglifehrin macrocycle. *Journal of Medicinal Chemistry*, *61*(21), 9473-9499.

[Record #146 is using a reference type undefined in this output style.]

McCoull, W., Abrams, R. D., Anderson, E., Blades, K., Barton, P., Box, M., Burgess, J., Byth, K., Cao, Q., & Chuaqui, C. (2017). Discovery of pyrazolo [1, 5-a] pyrimidine B-cell lymphoma 6 (BCL6) binders and optimization to high affinity macrocyclic inhibitors. *Journal of Medicinal Chemistry*, *60*(10), 4386-4402.

McGowan, D., Vendeville, S., Lin, T. I., Tahri, A., Hu, L., Cummings, M. D., Amssoms, K., Berke, J. M., Canard, M., Cleiren, E., Dehertogh, P., Last, S., Fransen, E., Van Der Helm, E., Van den Steen, I., Vijgen, L., Rouan, M. C., Fanning, G., Nyanguile, O., Van Emelen, K., Simmen, K., & Raboisson, P. (2012). Finger-loop inhibitors of the HCV NS5b polymerase. Part 1: Discovery and optimization of novel 1,6- and 2,6-macrocyclic indole series. *Bioorg Med Chem Lett*, *22*(13), 4431-4436. <https://doi.org/10.1016/j.bmcl.2012.03.097>

Miyachi, H., Kanamitsu, K., Ishii, M., Watanabe, E., Katsuyama, A., Otsuguro, S., Yakushiji, F., Watanabe, M., Matsui, K., & Sato, Y. (2021). Structure, solubility, and permeability relationships in a diverse middle molecule library. *Bioorganic & Medicinal Chemistry Letters*, *37*, 127847.

Moore, K. P., Zhu, H., Rajapakse, H. A., McGaughey, G. B., Colussi, D., Price, E. A., Sankaranarayanan, S., Simon, A. J., Pudvah, N. T., Hochman, J. H., Allison, T., Munshi, S. K., Graham, S. L., Vacca, J. P., & Nantermet, P. G. (2007). Strategies toward improving the brain penetration of macrocyclic tertiary carbinamine BACE-1 inhibitors. *Bioorg Med Chem Lett*, *17*(21), 5831-5835. <https://doi.org/10.1016/j.bmcl.2007.08.040>

Moreau, B., O’Meara, J. A., Bordeleau, J. e., Garneau, M., Godbout, C., Gorys, V., Leblanc, M. l., Villemure, E., White, P. W., & Llinàs-Brunet, M. (2014). Discovery of hepatitis C virus NS3-4A protease inhibitors with improved barrier to resistance and favorable liver distribution. *Journal of Medicinal Chemistry*, *57*(5), 1770-1776.

Naylor, M. R., Ly, A. M., Handford, M. J., Ramos, D. P., Pye, C. R., Furukawa, A., Klein, V. G., Noland, R. P., Edmondson, Q., & Turmon, A. C. (2018). Lipophilic permeability efficiency reconciles the opposing roles of lipophilicity in membrane permeability and aqueous solubility. *Journal of Medicinal Chemistry*, *61*(24), 11169-11182.

Nilsson, M., Belfrage, A. K., Lindström, S., Wähling, H., Lindquist, C., Ayesa, S., Kahnberg, P., Pelcman, M., Benkestock, K., Agback, T., Vrang, L., Terelius, Y., Wikström, K., Hamelink, E., Rydergård, C., Edlund, M., Eneroth, A., Raboisson, P., Lin, T. I., de Kock, H., Wigerinck, P., Simmen, K., Samuelsson, B., & Rosenquist, S. (2010). Synthesis and SAR of potent inhibitors of the Hepatitis C virus NS3/4A protease: exploration of P2 quinazoline substituents. *Bioorg Med Chem Lett*, *20*(14), 4004-4011. <https://doi.org/10.1016/j.bmcl.2010.05.029>

Nožinić, D., Milić, A., Mikac, L., Ralić, J., Padovan, J., & Antolović, R. (2010). Assessment of macrolide transport using PAMPA, Caco-2 and MDCKII-hMDR1 assays. *Croatica chemica acta*, *83*(3), 323-331.

Over, B., Matsson, P., Tyrchan, C., Artursson, P., Doak, B. C., Foley, M. A., Hilgendorf, C., Johnston, S. E., Lee IV, M. D., & Lewis, R. J. (2016). Structural and conformational determinants of macrocycle cell permeability. *Nature Chemical Biology*, *12*(12), 1065-1074.

Parsy, C. C., Alexandre, F.-R., Bidau, V., Bonnaterre, F., Brandt, G., Caillet, C., Cappelle, S., Chaves, D., Convard, T., & Derock, M. (2015). Discovery and structural diversity of the hepatitis C virus NS3/4A serine protease inhibitor series leading to clinical candidate IDX320. *Bioorganic & Medicinal Chemistry Letters*, *25*(22), 5427-5436.

Pasero, C., D’Agostino, I., De Luca, F., Zamperini, C., Deodato, D., Truglio, G. I., Sannio, F., Del Prete, R., Ferraro, T., & Visaggio, D. (2018). Alkyl-guanidine compounds as potent broad-spectrum antibacterial agents: chemical library extension and biological characterization. *Journal of medicinal chemistry*, *61*(20), 9162-9176.

Peng, J., Kudrimoti, S., Prasanna, S., Odde, S., Doerksen, R. J., Pennaka, H. K., Choo, Y.-M., Rao, K. V., Tekwani, B. L., & Madgula, V. (2010). Structure− activity relationship and mechanism of action studies of manzamine analogues for the control of neuroinflammation and cerebral infections. *Journal of Medicinal Chemistry*, *53*(1), 61-76.

Raboisson, P., de Kock, H., Rosenquist, A., Nilsson, M., Salvador-Oden, L., Lin, T. I., Roue, N., Ivanov, V., Wähling, H., Wickström, K., Hamelink, E., Edlund, M., Vrang, L., Vendeville, S., Van de Vreken, W., McGowan, D., Tahri, A., Hu, L., Boutton, C., Lenz, O., Delouvroy, F., Pille, G., Surleraux, D., Wigerinck, P., Samuelsson, B., & Simmen, K. (2008). Structure-activity relationship study on a novel series of cyclopentane-containing macrocyclic inhibitors of the hepatitis C virus NS3/4A protease leading to the discovery of TMC435350. *Bioorg Med Chem Lett*, *18*(17), 4853-4858. <https://doi.org/10.1016/j.bmcl.2008.07.088>

Raboisson, P., Lin, T. I., Kock, H., Vendeville, S., Vreken, W. V., McGowan, D., Tahri, A., Hu, L., Lenz, O., Delouvroy, F., Surleraux, D., Wigerinck, P., Nilsson, M., Rosenquist, S., Samuelsson, B., & Simmen, K. (2008). Discovery of novel potent and selective dipeptide hepatitis C virus NS3/4A serine protease inhibitors. *Bioorg Med Chem Lett*, *18*(18), 5095-5100. <https://doi.org/10.1016/j.bmcl.2008.07.124>

Randolph, J. T., Voight, E. A., Greszler, S. N., Uno, B. E., Newton, J. N., Gleason, K. M., Stolarik, D., Van Handel, C., Bow, D. A., & DeGoey, D. A. (2020). Prodrug strategies to improve the solubility of the HCV NS5A inhibitor pibrentasvir (ABT-530). *Journal of Medicinal Chemistry*, *63*(19), 11034-11044.

Rescourio, G., Gonzalez, A. Z., Jabri, S., Belmontes, B., Moody, G., Whittington, D., Huang, X., Caenepeel, S., Cardozo, M., & Cheng, A. C. (2019). Discovery and in vivo evaluation of macrocyclic Mcl-1 inhibitors featuring an α-hydroxy phenylacetic acid pharmacophore or bioisostere. *Journal of Medicinal Chemistry*, *62*(22), 10258-10271.

Richter, J. M., Cheney, D. L., Bates, J. A., Wei, A., Luettgen, J. M., Rendina, A. R., Harper, T. M., Narayanan, R., Wong, P. C., & Seiffert, D. (2017). Design and synthesis of novel meta-linked phenylglycine macrocyclic FVIIa inhibitors. *ACS Medicinal Chemistry Letters*, *8*(1), 67-72.

Rosenquist, Å., Samuelsson, B., Johansson, P.-O., Cummings, M. D., Lenz, O., Raboisson, P., Simmen, K., Vendeville, S., de Kock, H., & Nilsson, M. (2014). Discovery and development of simeprevir (TMC435), a HCV NS3/4A protease inhibitor. *Journal of Medicinal Chemistry*, *57*(5), 1673-1693.

Rossi Sebastiano, M., Doak, B. C., Backlund, M., Poongavanam, V., Over, B. r., Ermondi, G., Caron, G., Matsson, P. r., & Kihlberg, J. (2018). Impact of dynamically exposed polarity on permeability and solubility of chameleonic drugs beyond the rule of 5. *Journal of Medicinal Chemistry*, *61*(9), 4189-4202.

Rzepiela, A. A., Viarengo-Baker, L. A., Tatarskii, V., Kombarov, R., & Whitty, A. (2022). Conformational effects on the passive membrane permeability of synthetic macrocycles. *Journal of Medicinal Chemistry*, *65*(15), 10300-10317.

Saunders, G. J., & Yudin, A. K. (2022). Property-Driven Development of Passively Permeable Macrocyclic Scaffolds Using Heterocycles\*\*. *Angewandte Chemie International Edition*, *61*(33), e202206866. <https://doi.org/https://doi.org/10.1002/anie.202206866>

Spencer, J. A., Baldwin, I. R., Barton, N., Chung, C.-W., Convery, M. A., Edwards, C. D., Jamieson, C., Mallett, D. N., Rowedder, J. E., & Rowland, P. (2020). Design and development of a macrocyclic series targeting phosphoinositide 3-Kinase δ. *ACS Medicinal Chemistry Letters*, *11*(7), 1386-1391.

Stachel, S. J., Coburn, C. A., Sankaranarayanan, S., Price, E. A., Pietrak, B. L., Huang, Q., Lineberger, J., Espeseth, A. S., Jin, L., & Ellis, J. (2006). Macrocyclic inhibitors of β-secretase: functional activity in an animal model. *Journal of Medicinal Chemistry*, *49*(21), 6147-6150.

Stefanucci, A., Dimmito, M. P., Macedonio, G., Ciarlo, L., Pieretti, S., Novellino, E., Lei, W., Barlow, D., Houseknecht, K. L., & Streicher, J. M. (2019). Potent, efficacious, and stable cyclic opioid peptides with long lasting antinociceptive effect after peripheral administration. *Journal of Medicinal Chemistry*, *63*(5), 2673-2687.

Sund, C., Belda, O., Wiktelius, D., Sahlberg, C., Vrang, L., Sedig, S., Hamelink, E., Henderson, I., Agback, T., Jansson, K., Borkakoti, N., Derbyshire, D., Eneroth, A., & Samuelsson, B. (2011). Design and synthesis of potent macrocyclic renin inhibitors. *Bioorg Med Chem Lett*, *21*(1), 358-362. <https://doi.org/10.1016/j.bmcl.2010.10.140>

Tess, D. A., Eng, H., Kalgutkar, A. S., Litchfield, J., Edmonds, D. J., Griffith, D. A., & Varma, M. V. (2020). Predicting the human hepatic clearance of acidic and zwitterionic drugs. *Journal of Medicinal Chemistry*, *63*(20), 11831-11844.

Tyagi, M., Poongavanam, V., Lindhagen, M., Pettersen, A., Sjö, P., Schiesser, S., & Kihlberg, J. (2018). Toward the Design of Molecular Chameleons: Flexible Shielding of an Amide Bond Enhances Macrocycle Cell Permeability. *Organic Letters*, *20*(18), 5737-5742. <https://doi.org/10.1021/acs.orglett.8b02447>

Vendeville, S., Nilsson, M., de Kock, H., Lin, T. I., Antonov, D., Classon, B., Ayesa, S., Ivanov, V., Johansson, P. O., Kahnberg, P., Eneroth, A., Wikstrom, K., Vrang, L., Edlund, M., Lindström, S., Van de Vreken, W., McGowan, D., Tahri, A., Hu, L., Lenz, O., Delouvroy, F., Van Dooren, M., Kindermans, N., Surleraux, D., Wigerinck, P., Rosenquist, A., Samuelsson, B., Simmen, K., & Raboisson, P. (2008). Discovery of novel, potent and bioavailable proline-urea based macrocyclic HCV NS3/4A protease inhibitors. *Bioorg Med Chem Lett*, *18*(23), 6189-6193. <https://doi.org/10.1016/j.bmcl.2008.10.004>

Wang, C., Li, J., Qu, L., Tang, X., Song, X., Yang, F., Chen, X., Lin, Q., Lin, W., & Zhou, Y. (2022). Discovery of D6808, a highly selective and potent macrocyclic c-met inhibitor for gastric cancer harboring MET gene alteration treatment. *Journal of Medicinal Chemistry*, *65*(22), 15140-15164.

Wang, L., Pratt, J. K., Soltwedel, T., Sheppard, G. S., Fidanze, S. D., Liu, D., Hasvold, L. A., Mantei, R. A., Holms, J. H., & McClellan, W. J. (2017). Fragment-based, structure-enabled discovery of novel pyridones and pyridone macrocycles as potent bromodomain and extra-terminal domain (BET) family bromodomain inhibitors. *Journal of Medicinal Chemistry*, *60*(9), 3828-3850.

Wang, Q., Sciabola, S., Barreiro, G., Hou, X., Bai, G., Shapiro, M. J., Koehn, F., Villalobos, A., & Jacobson, M. P. (2016). Dihedral angle-based sampling of natural product polyketide conformations: application to permeability prediction. *Journal of Chemical Information and Modeling*, *56*(11), 2194-2206.

Wieske, L. H., Atilaw, Y., Poongavanam, V., Erdélyi, M., & Kihlberg, J. (2023). Going viral: an investigation into the chameleonic behaviour of antiviral compounds. *Chemistry–A European Journal*, *29*(8), e202202798.

William, A. D., Lee, A. C.-H., Blanchard, S., Poulsen, A., Teo, E. L., Nagaraj, H., Tan, E., Chen, D., Williams, M., & Sun, E. T. (2011). Discovery of the Macrocycle 11-(2-Pyrrolidin-1-yl-ethoxy)-14, 19-dioxa-5, 7, 26-triaza-tetracyclo [19.3. 1.1 (2, 6). 1 (8, 12)] heptacosa-1 (25), 2 (26), 3, 5, 8, 10, 12 (27), 16, 21, 23-decaene (SB1518), a Potent Janus Kinase 2/Fms-Like Tyrosine Kinase-3 (JAK2/FLT3) Inhibitor for the Treatment of Myelofibrosis and Lymphoma. *Journal of Medicinal Chemistry*, *54*(13), 4638-4658.

William, A. D., Lee, A. C.-H., Goh, K. C., Blanchard, S. p., Poulsen, A., Teo, E. L., Nagaraj, H., Lee, C. P., Wang, H., & Williams, M. (2012). Discovery of kinase spectrum selective macrocycle (16 e)-14-methyl-20-oxa-5, 7, 14, 26-tetraazatetracyclo [19.3. 1.1 (2, 6). 1 (8, 12)] heptacosa-1 (25), 2 (26), 3, 5, 8 (27), 9, 11, 16, 21, 23-decaene (SB1317/TG02), a potent inhibitor of cyclin dependent kinases (cdks), janus kinase 2 (jak2), and fms-like tyrosine kinase-3 (flt3) for the treatment of cancer. *Journal of Medicinal Chemistry*, *55*(1), 169-196.

William, A. D., Lee, A. C.-H., Poulsen, A., Goh, K. C., Madan, B., Hart, S., Tan, E., Wang, H., Nagaraj, H., & Chen, D. (2012). Discovery of the Macrocycle (9 E)-15-(2-(Pyrrolidin-1-yl) ethoxy)-7, 12, 25-trioxa-19, 21, 24-triaza-tetracyclo [18.3. 1.1 (2, 5). 1 (14, 18)] hexacosa-1 (24), 2, 4, 9, 14 (26), 15, 17, 20, 22-nonaene (SB1578), a Potent Inhibitor of Janus Kinase 2/Fms-LikeTyrosine Kinase-3 (JAK2/FLT3) for the Treatment of Rheumatoid Arthritis. *Journal of Medicinal Chemistry*, *55*(6), 2623-2640.

Wuelfing, W. P., El Marrouni, A., Lipert, M. P., Daublain, P., Kesisoglou, F., Converso, A., & Templeton, A. C. (2022). Dose number as a tool to guide lead optimization for orally bioavailable compounds in drug discovery. *Journal of Medicinal Chemistry*, *65*(3), 1685-1694.

Wurtz, N. R., Parkhurst, B. L., DeLucca, I., Glunz, P. W., Jiang, W., Zhang, X., Cheney, D. L., Bozarth, J. M., Rendina, A. R., & Wei, A. (2017). Neutral macrocyclic factor VIIa inhibitors. *Bioorganic & Medicinal Chemistry Letters*, *27*(12), 2650-2654.

Xiao, T., Sun, L., Zhang, M., Li, Z., Haura, E. B., Schonbrunn, E., & Ji, H. (2021). Synthesis and structural characterization of a monocarboxylic inhibitor for GRB2 SH2 domain. *Bioorganic & Medicinal Chemistry Letters*, *51*, 128354.

Xin, Z., Himmelbauer, M. K., Jones, J. H., Enyedy, I., Gilfillan, R., Hesson, T., King, K., Marcotte, D. J., Murugan, P., & Santoro, J. C. (2020). Discovery of CNS-penetrant apoptosis signal-regulating kinase 1 (ASK1) inhibitors. *ACS Medicinal Chemistry Letters*, *11*(4), 485-490.

Xu, H., Roberts, L. R., Chou, S., Pierce, B., Narayanan, A., & Jones, L. H. (2017). Quantitative measurement of intracellular HDAC1/2 drug occupancy using a trans-cyclooctene largazole thiol probe. *MedChemComm*, *8*(4), 767-770.

Xue, S.-t., Zhang, L., Xie, Z.-s., Jin, J., Guo, H.-F., Yi, H., Liu, Z.-y., & Li, Z.-r. (2020). Substituted benzothiophene and benzofuran derivatives as a novel class of bone morphogenetic Protein-2 upregulators: Synthesis, anti-osteoporosis efficacies in ovariectomized rats and a zebrafish model, and ADME properties. *European Journal of Medicinal Chemistry*, *200*, 112465.

Yamaguchi-Sasaki, T., Kawaguchi, T., Okada, A., Tokura, S., Tanaka-Yamamoto, N., Takeuchi, T., Ogata, Y., Takahashi, R., Kurimoto-Tsuruta, R., Tamaoki, T., Sugaya, Y., Abe-Kumasaka, T., Arikawa, K., Yoshida, I., Sugiyama, H., Kanuma, K., & Yoshinaga, M. (2020). Discovery of a potent dual inhibitor of wild-type and mutant respiratory syncytial virus fusion proteins through the modulation of atropisomer interconversion properties. *Bioorg Med Chem*, *28*(24), 115818. <https://doi.org/10.1016/j.bmc.2020.115818>

[Record #147 is using a reference type undefined in this output style.]

Yang, W., Wang, Y., Lai, A., Clark, C. G., Corte, J. R., Fang, T., Gilligan, P. J., Jeon, Y., Pabbisetty, K. B., & Rampulla, R. A. (2020). Discovery of a high affinity, orally bioavailable macrocyclic FXIa inhibitor with antithrombotic activity in preclinical species. *Journal of Medicinal Chemistry*, *63*(13), 7226-7242.

Zhang, H., Ginn, J., Zhan, W., Liu, Y. J., Leung, A., Toita, A., Okamoto, R., Wong, T.-T., Imaeda, T., & Hara, R. (2022). Mayako Michino-Jeremie Vendome. *Journal of Medicinal Chemistry*.

Zhang, H., Hsu, H.-C., Kahne, S. C., Hara, R., Zhan, W., Jiang, X., Burns-Huang, K., Ouellette, T., Imaeda, T., & Okamoto, R. (2021). Macrocyclic peptides that selectively inhibit the Mycobacterium tuberculosis proteasome. *Journal of Medicinal Chemistry*, *64*(9), 6262-6272.

Zhang, X., Glunz, P. W., Johnson, J. A., Jiang, W., Jacutin-Porte, S., Ladziata, V., Zou, Y., Phillips, M. S., Wurtz, N. R., & Parkhurst, B. (2016). Discovery of a highly potent, selective, and orally bioavailable macrocyclic inhibitor of blood coagulation factor VIIa–tissue factor complex. *Journal of Medicinal Chemistry*, *59*(15), 7125-7137.

Zheng, M., Li, C., Zhou, M., Jia, R., Cai, G., She, F., Wei, L., Wang, S., Yu, J., & Wang, D. (2021). Discovery of cyclic peptidomimetic ligands targeting the extracellular domain of EGFR. *Journal of Medicinal Chemistry*, *64*(15), 11219-11228.